No Data
No Data
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
Hong Kong stocks moved differently | Most CRO Concept stocks rose, the momentum for the development of biopharmaceuticals continues, UBS Group is Bullish on the recent earnings prospects of the CRO Industry.
Most CRO concept stocks have risen. As of the time of writing, WUXI BIO (02269) is up 3.28% at HKD 17.02; WUXI APPTEC (02359) is up 3.03% at HKD 52.65; PHARMARON (03759) is up 1.72% at HKD 13.02; Asymchem Laboratories (06821) is up 1.16% at HKD 47.85.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
Asymchem Laboratories (002821.SZ): Cumulatively repurchased 3.6161% of shares.
On January 3rd, GELONGHUI reported that Asymchem Laboratories (002821.SZ) announced that as of December 31, 2024, the cumulative number of shares repurchased through a special securities account via centralized bidding was 12,300,701 shares, accounting for 3.6161% of the company's total A-share capital, with a highest Fill Price of 102.00 yuan/share, a lowest Fill Price of 71.65 yuan/share, and the total amount paid was 999,644,601.56 yuan (excluding trading fees).
Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Shares Not Telling The Full Story
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
No Data